ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2026
Opportunities to Avoid Invasive Cancer by Diagnosis and Interception of Preneoplastic Lesions and Cancer Risk Conditions.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPreneoplastic lesions (PNL) represent a state intermediate between normal cells and invasive cancer. Individuals diagnosed with PNL are at increased risk of developing invasive cancer and represent a unique risk group. We estimated the proportion of invasive cancer that could be intercepted at multiple anatomic sites in individuals with PNL.
methodsUsing a literature survey of the prevalence, latency, and probability of progression of PNL to invasive cancer, we undertook a sensitivity analysis across proportions of invasive cancer from 5% to 95% that could be intercepted in a cohort of 100,000 individuals that would be avoided if PNL interception was successful. To calculate the number of avoidable invasive cancers, we used data that represent population-based, high-risk, unselected, and selected PNL case series and calculated the sensitivities and specificities of avoidable invasive cancers.
resultsSubstantial invasive cancer reductions could be achieved by the interception of PNL that precede pancreas, gastric, bladder, prostate, breast, colorectal, and skin cancers. An intermediate reduction in cancer incidence was observed for lung and oral cancers. Limited impact on the global burden of cancer with the interception of PNL is likely for cervical, liver, and esophageal cancer, as well as myeloma and leukemia. Due to the estimates representing varying populations, the impacts of a specific PNL or cancer cannot be compared with another.
conclusionsWe identified substantial variation in the impact that the interception of PNL would have on the development of invasive cancer. IMPACT: These results may guide research and implementation of studies intended to maximize the number of invasive cancers that can be avoided by the interception of PNL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.